| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P6179 | Dimensions Publication ID | 1021576429 |
| P356 | DOI | 10.1186/S13643-015-0118-Z |
| P8608 | Fatcat ID | release_froeqwgucvhetdjxsfzofoazgq |
| P932 | PMC publication ID | 4591587 |
| P698 | PubMed publication ID | 26428301 |
| P5875 | ResearchGate publication ID | 282425460 |
| P2093 | author name string | Mary S Beattie | |
| Sara Hurvitz | |||
| Anne Morris | |||
| Bindu Kalesan | |||
| Isabel Elaine Allen | |||
| Eli J Korner | |||
| P2860 | cites work | Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer | Q48624908 |
| Systematic Reviews in Health Care | Q56528741 | ||
| Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) | Q56529840 | ||
| Quality of Reporting of Randomized Trials as a Measure of Methodologic Quality | Q56536731 | ||
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
| A Coefficient of Agreement for Nominal Scales | Q57167717 | ||
| Users' Guides to the Medical Literature | Q57169696 | ||
| Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers | Q59487524 | ||
| Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group | Q72038815 | ||
| Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group | Q72234622 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | Q27860581 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses | Q28131633 | ||
| The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy | Q28191663 | ||
| Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit | Q28254604 | ||
| A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints | Q29614902 | ||
| Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography | Q29615697 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| Systematic reviews of evaluations of prognostic variables | Q33806488 | ||
| Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations | Q34982587 | ||
| Factors influencing inclusion of patients with malignancies in clinical trials | Q36362504 | ||
| Evaluation of the quality of prognosis studies in systematic reviews | Q36426632 | ||
| Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis | Q36630997 | ||
| Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry | Q37185996 | ||
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 | ||
| Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists | Q37808838 | ||
| Different methods of allocation to groups in randomized trials are associated with different levels of bias. A meta-epidemiological study | Q37862851 | ||
| The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers | Q38151305 | ||
| Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline | Q38209628 | ||
| Perspectives on prognosis of soft tissue musculoskeletal disorders | Q40826718 | ||
| Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer | Q41756399 | ||
| Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 | ||
| Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer | Q48371008 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 133 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Systematic Reviews | Q18216009 |
| P1476 | title | NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer | |
| P478 | volume | 4 |
Search more.